Will The $3bn Stimulus Amid COVID-19 Place Indian Cos Among Goliaths?

INR 51bn Investments Committed Under First PLI Scheme

Following an INR69bn incentive scheme for APIs, the Indian government has come up with an INR150bn scheme for formulations and more. Will this $3bn push prove to be the one that companies like Sun Pharma and Aurobindo, currently at 36 and 48 respectively in Scrip 100 rankings, need to break into the top league?

Businessman overtaking businessman climbing stairs using rocket engine. Career progress
Is This The Booster Indian Industry Has Been Looking For? • Source: Shutterstock

It’s not every day that a government rolls out a large fiscal stimulus, but supply disruptions due to COVID-19, the current government’s ‘Make In India’ push and a persistent realization of a dependence on China have prompted not one but two schemes by the Indian government with potential to boost India’s manufacturing capability.

After a profit-linked incentive (PLI) scheme introduced in 2020 for production of certain critical raw materials like penicillin G, the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Manufacturing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.